STANFORD UNIVERSITY

Stanford, CA 94305 [Mail Code 5579]

Michael D. Amylon, M.D. 650-724-2950
CHAIR, PANEL ON MEDICAL HUMAN SUBJECTS 650-725-8013

Certification of Human Subjects Approvals

Date: February 8, 2026

To: Teddy Akiki, MD, Psych/Major Laboratories and Clinical & Translational Neurosciences Incubator

Isabelle Page Wydler BA, Leanne Williams null, Erica Ma MS, PA-C, Andrea Ellsay, Conner James Oberhauser, Gracie Johanna Grimsrud, Jeesung Ahn PhD, Laura Michele Hack MD, PhD, Leyla Boyar BA, Lucas P. Wozniak, Peter Johannes van Roessel MD, PhD, Rachel Hilton, Rio Juliana Hundley

From: Michael D. Amylon, M.D., Administrative Panel on Human Subjects in Medical Research

eProtocol Stratified Pharmacological Approaches for Regulating Circuit-Level Effects (SPARCLE)

eProtocol #: 80975 **IRB 7** **(Registration** 5136)

Overall risk level: Greater than minimal risk

The IRB approved human subjects involvement in your research project on 02/08/2026. **'Prior to subject recruitment and enrollment, if this is: a Cancer-related study, you must obtain Cancer Center Scientific Review Committee (SRC) approval;** a CTRU study, you must obtain CTRU approval; a VA study, you must obtain VA R and D Committee approval; and **if a contract is involved, it must be signed.**'

The expiration date of this approval is 08/13/2026 at Midnight. If this research is to continue beyond that date, it is your responsibility to submit a Continuing Review application in eProtocol. Research activities must be reviewed and re-approved on or before midnight of the expiration date. The approval period may be less than one year if so determined by the IRB. Proposed changes to approved research must be reviewed and approved prospectively by the IRB. Except where necessary to eliminate apparent immediate hazards to subjects, all research activities must halt if there is a lapse in approval, and no changes may be initiated without prior approval by the IRB. (Any such exceptions must be reported to the IRB within 10 working days.) Unanticipated problems involving risks to participants or others and other events or information, as defined and listed in the Report Form, must be submitted promptly to the IRB. (See Events and Information that Require Prompt Reporting to the IRB at http://humansubjects.stanford.edu.) Upon completion, you must report to the IRB within 30 days.

Please remember that all data, including all signed consent form documents, must be retained for a minimum of three years past the completion of this research. Additional requirements may be imposed by your funding agency, your department, or other entities. (See Policy 1.9 on Retention of and Access to Research Data at http://doresearch.stanford.edu/policies/research-policy-handbook)

This institution is in compliance with requirements for protection of human subjects, including 45 CFR 46.

Waiver of Authorization for recruitment 45 CFR 164.512(i)(2)(ii)(A),(B),(C).
Waiver of Documentation of Consent 56.109(c)(1)(iii)
NSR Device.

Michael D. Amylon, M.D., Chair

Approval Period: 02/08/2026 - 08/13/2026
Review Type: REGULAR - MODIFICATION
Overall risk level: Greater than minimal risk
Funding: National Institutes of Health - Grant: 5U01MH136062-02, SPO: 304028

Assurance #:

LELAND STANFORD JUNIOR UNIVERSITY
DIE LUFT DER FREIHEIT WEHT
1891

STANFORD UNIVERSITY

Stanford, CA 94305 [Mail Code 5579]

Michael D. Amylon, M.D. 650-724-2950
CHAIR, PANEL ON MEDICAL HUMAN SUBJECTS 650-725-8013

Certification of Human Subjects Approvals

Date: February 8, 2026

To: Teddy Akiki, MD, Psych/Major Laboratories and Clinical & Translational Neurosciences Incubator

Isabelle Page Wydler BA, Leanne Williams null, Erica Ma MS, PA-C, Andrea Ellsay, Conner James Oberhauser, Gracie Johanna Grimsrud, Jeesung Ahn PhD, Laura Michele Hack MD, PhD, Leyla Boyar BA, Lucas P. Wozniak, Peter Johannes van Roessel MD, PhD, Rachel Hilton, Rio Juliana Hundley

From: Michael D. Amylon, M.D., Administrative Panel on Human Subjects in Medical Research

eProtocol Stratified Pharmacological Approaches for Regulating Circuit-Level Effects (SPARCLE)

eProtocol #: 80975 **IRB 7** **(Registration** 5136)

Overall risk level: Greater than minimal risk

The IRB approved human subjects involvement in your research project on 02/08/2026. **'Prior to subject recruitment and enrollment, if this is: a Cancer-related study, you must obtain Cancer Center Scientific Review Committee (SRC) approval;** a CTRU study, you must obtain CTRU approval; a VA study, you must obtain VA R and D Committee approval; and **if a contract is involved, it must be signed.**'

The expiration date of this approval is 08/13/2026 at Midnight. If this research is to continue beyond that date, it is your responsibility to submit a Continuing Review application in eProtocol. Research activities must be reviewed and re-approved on or before midnight of the expiration date. The approval period may be less than one year if so determined by the IRB. Proposed changes to approved research must be reviewed and approved prospectively by the IRB. Except where necessary to eliminate apparent immediate hazards to subjects, all research activities must halt if there is a lapse in approval, and no changes may be initiated without prior approval by the IRB. (Any such exceptions must be reported to the IRB within 10 working days.) Unanticipated problems involving risks to participants or others and other events or information, as defined and listed in the Report Form, must be submitted promptly to the IRB. (See Events and Information that Require Prompt Reporting to the IRB at http://humansubjects.stanford.edu.) Upon completion, you must report to the IRB within 30 days.

Please remember that all data, including all signed consent form documents, must be retained for a minimum of three years past the completion of this research. Additional requirements may be imposed by your funding agency, your department, or other entities. (See Policy 1.9 on Retention of and Access to Research Data at http://doresearch.stanford.edu/policies/research-policy-handbook)

This institution is in compliance with requirements for protection of human subjects, including 45 CFR 46.

Waiver of Authorization for recruitment 45 CFR 164.512(i)(2)(ii)(A),(B),(C).
Waiver of Documentation of Consent 56.109(c)(1)(iii)
NSR Device.

Michael D. Amylon, M.D., Chair

Approval Period: 02/08/2026 - 08/13/2026
Review Type: REGULAR - MODIFICATION
Overall risk level: Greater than minimal risk
Funding: Dolby Family Foundation

Assurance #:

LELAND STANFORD JUNIOR UNIVERSITY
DIE LUFT DER FREIHEIT WEHT
1891